Last 12mo stats

mentions

voices

$BDTX

Black Diamond Therapeutics

Share on X

$BDTX

Black Diamond Therapeutics

Past 12mo:16mentions1voices

Share on X

All voices16 mentions since Dec 2025calls only

Loading price chart…

Frequently asked

Who mentions $BDTX most on Surfaced?

@jacobplieth (Jacob Plieth) mentions $BDTX most — 16 mentions in the past 12 months.

When was $BDTX first mentioned on Surfaced?

The earliest tracked mention of $BDTX in the Surfaced archive was on Dec 3, 2025.

How many voices track $BDTX?

1 FinTwit voice has mentioned $BDTX 16 times in the past 12 months.

What kind of voices mention $BDTX most?

$BDTX is mentioned most by Biotech voices on Surfaced.

Recent mentions

16 mentions

@jacobpliethMay 22, 2026 · 1:33 PM

$BDTX opens off 20%. Here's why, via @ApexOnco -> https://t.co/Ep7ssF1uTy #ASCO26

Open on X

@jacobpliethMay 22, 2026 · 1:05 PM

@Miljenkoz "Not the best." Yes, that's one way to put it $BDTX #ASCO26 https://t.co/URArM4awgw

Open on X

@jacobpliethMay 22, 2026 · 12:24 PM

@avidresearch The fact tox has forced $BDTX to take 150mg (instead of 200mg) forward is not good.

Open on X

@jacobpliethMay 22, 2026 · 9:30 AM

@BiotechCLin Indeed. And this concerns 200mg, which is no longer relevant. Expect 150mg to do worse $BDTX

Open on X

@jacobpliethMay 22, 2026 · 8:39 AM

Looks like tox is the biggest worry now for silevertinib. 60% gr3 TRAE for the 200mg dose tested. $BDTX now hoping to take 150mg into registrational trial #ASCO26

Open on X

@jacobpliethMay 22, 2026 · 8:28 AM

Cross-trial mPFS comparison for $BDTX is $AVBP, which clailmed 16.0 months in 1st-line PACCm patients at #WCLC25.

Open on X

@jacobpliethMay 22, 2026 · 8:24 AM

$BDTX old & updated waterfalls from silevertinib study in 1st-line NSCLC with non-classical mutations, at #ASCO26. ORR 60% is unchanged vs Dec 2025. mPFS 15.2mth is newly disclosed (appears higher than anecdotal ~10mth with off-label Gilotrif). https://t.co/aYpkzPveUl

Open on X

@jacobpliethDec 5, 2025 · 1:58 PM

Now $ORIC goes after $AVBP & $BDTX in 1st-line PACC lung cancer, and shows why it abandoned relapsed HER2 ex20. Via @ApexOnco -> https://t.co/valRcL0Fvd https://t.co/AITjRMe1sC

Open on X

@jacobpliethDec 3, 2025 · 4:22 PM

$BDTX currently off 17% (earlier -30%) on yet another strategic pivot. @ApexOnco take on today's silevertinib data https://t.co/gaR3OPzVPM $AVBP

Open on X

@jacobpliethDec 3, 2025 · 3:01 PM

@Ozymand36063774 @LionsWatson The promising setting (NSCLC) $BDTX can't afford to fund, so instead it's funding pivotal development in GBM, where silevertinib has yet to show any meaningful activity.

Open on X

@jacobpliethDec 3, 2025 · 2:45 PM

@LionsWatson ...but do feel free to use this as a "buying opportunity" LOL $BDTX https://t.co/jLHr5J7gCh

Open on X

@jacobpliethDec 3, 2025 · 2:02 PM

@LionsWatson I'm so sorry for being insufficiently enthusiastic with my praise for $BDTX. Anyway, here's $AVBP https://t.co/ldDzAdxPGc

Open on X

@jacobpliethDec 3, 2025 · 1:18 PM

@ErikOtto2 $BDTX ORR in non-classical, non-PACC EGFR mutations seems to be 67% (12/18), according to my calc https://t.co/Hi1kdUISTP

Open on X

@jacobpliethDec 3, 2025 · 1:12 PM

Silevertinib in 1L NSCLC non-classical mutations. Data look decent, but $BDTX needs a partner to fund pivotal development https://t.co/0MmOHChwdB

Open on X

@jacobpliethDec 3, 2025 · 12:28 PM

...or is this the regulatory update: no accelerated pathway, needs pivotal trial, and $BDTX can't run this without a partner.

Open on X

@jacobpliethDec 3, 2025 · 12:25 PM

I thought we were expecting $BDTX to reveal what regulatory pathway it's planning for silevertinib.

Open on X